The global glaucoma treatment market holds a valuation of US$ 5.7 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 3.18%, and is expected to hold a market value of around US$ 8.0 Billion in 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 5.7 Billion |
| Market Value 2023 | US$ 5.8 Billion |
| Market Value 2033 | US$ 8.0 Billion |
| CAGR 2023 to 2033 | 3.2% |
| Market Share of Top 5 Countries (2022) | 55.2% |
| Key Market Players | AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd. |
Glaucoma is the most common and second leading eye diseases and causes irreversible blindness by damaging optic nerve by high eye pressure. The common glaucoma type is open angle glaucoma causes vision loss with no apparent symptoms, while angle closure glaucoma is infrequent glaucoma and occurs with symptoms like eye pain with visual disturbance, and nausea. Glaucoma aetiology includes age-related macular degeneration, cataract, diabetic retinopathy, glaucoma, uncorrected refractive errors, and other factors.
According to the World Health Organization (WHO), about 4.5 million people suffers from glaucoma globally in 2019. As per published data of National Glaucoma Research data in 2022, currently glaucoma patients are more than 80 million and it is anticipated to increase beyond 111 million till 2040.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The glaucoma treatment industry expanded at a CAGR of 3.0% for 2017 to 2022 period due to increasing prevalence of glaucoma disease and diabetes, old - age population, and innovative technologies with novel pharmacological discoveries.
The global glaucoma treatment market contributes 15.9% value share to the global eye disorders and treatment market valued at US$ 35.8 Billion in 2022.
The glaucoma condition is frequently known as silent thief of sigh since most of the glaucoma variations rarely show pain or other obvious signs before causing noticeable vision loss; hence, number of glaucoma cases are rising. Government and pharmaceutical company activities are raising awareness of glaucoma are promoting the expansion of the market for glaucoma treatments.
Another factor driving the expansion of the market of glaucoma treatment is technological development in eye drops, which are the primary glaucoma control measure. Pharmaceutical and biotech businesses are also investing in the creation of novel glaucoma products. The most common medications used to treat glaucoma today include alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogues, and combinations of these drugs. In contrast, the absence of discomfort and symptoms other than apparent vision loss are regarded as a problem for the market of glaucoma treatment.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 2.44% |
| Jul-Dec (H2), 2021 (A) | 3.55% |
| Jan-Jun (H1),2022 Projected (P) | 2.33% |
| Jan-Jun (H1),2022 Outlook (O) | 2.57% |
| Jul-Dec (H2), 2022 Outlook (O) | 3.39% |
| Jul-Dec (H2), 2022 Projected (P) | 3.19% |
| Jan-Jun (H1), 2023 Projected (P) | 2.70% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 24 ↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 13 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 20 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (A) | (-) 17 ↓ |
Principal Consultant
Rising elderly populations and glaucoma awareness in several countries, as well as an increase in government and private sector initiatives to cure glaucoma and reduce the financial treatment cost, are expected to drive the glaucoma market demand.
An increase in the number of new innovative products and clinical trial products is boosting the industry's growth. The University of Minnesota College of Pharmacy's Department of Medicinal Chemistry and the Institute for Therapeutics Discovery & Development (ITDD) collaborated to create a novel medicine for the treatment of glaucoma in 2022.
The market is primarily driven by the ophthalmology industry's rapid technical advancements and the growing use of innovative surgical methods. The need for optometrists has grown as a result of advancements in optical coherence tomography (OCT), selective laser trabeculoplasty (SLT), medical imaging, progression analysis software, and microinvasive glaucoma surgery (MIGS). This is one of the key driving forces for the market's expansion. The size of the glaucoma market is anticipated to increase with the introduction of laser therapy and pharmaceuticals for the condition.
It is challenging to treat glaucoma because it does not initially cause symptoms like pain or vision loss. Glaucoma surgery also frequently results in a number of post-operative problems. Shortage of experienced healthcare workers and a lack of knowledge about glaucoma treatment in emerging nations may impede the growth of the industry of glaucoma treatment in the years to come.
The glaucoma drug approval process is stringent, and sometimes need to remove or reject a product from market due to safety issues concerns and also, by various other reasons, including bioavailability, drug performance, efficacy, PH properties, toxicity. Apotex Corp, for example, is recalling 22,027 bottles of timolol maleate ophthalmic solution in 2023 due to drug samples failed to meet stability specifications.
Drug side effects are also associated with glaucoma treatment. Prostaglandin analogues, for example, have side effects such as eye redness and itching; beta blockers have side effects such as low blood pressure and decreased libido; and Rho kinase inhibitors have side effects such as stinging and small bleeds on the white part of the eye.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 29.7% |
| Market Share (2033) | 29.8% |
| BPS Analysis | 9 |
| Country | China |
|---|---|
| Market Share (2023) | 11.1% |
| Market Share (2033) | 11.3% |
| BPS Analysis | 21 |
| Country | Russia |
|---|---|
| Market Share (2023) | 5.6% |
| Market Share (2033) | 5.7% |
| BPS Analysis | 1 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.2% |
| Market Share (2033) | 5.4% |
| BPS Analysis | 25 |
| Country | Canada |
|---|---|
| Market Share (2023) | 4.1% |
| Market Share (2033) | 3.9% |
| BPS Analysis | -19 |
The USA will dominate the global market of glaucoma treatment in 2023 with a market share of 29.7% in global glaucoma treatment market. The rising prevalence of various types of glaucoma in the region would boost the demand for glaucoma therapies.
The market will grow as more people become aware of the importance of eye care and the associated diagnoses and treatments. The region's significant presence of important market companies involved in new drug research and product approvals would boost regional industry growth.
Due to the increased glaucoma incidence and improved healthcare infrastructure, the United States is likely to be the largest glaucoma treatment industry. According to the BrightFocus Foundation, more than 3 million Americans are affected by glaucoma, with open-angle glaucoma being the most frequent type.
Glaucoma costs the USA economy around USD 2.86 billion in direct costs and productivity losses each year. Many organizations in the United States are raising awareness of glaucoma, which is projected to boost the market's overall growth.
Germany will hold the market share of 5.2% for its glaucoma treatment in 2023 global market.
Glaucoma is one of the leading causes of blindness in the world. Around 500,000 people in Germany have high intraocular pressure, and 10% of them are at risk of going blind. The number of unreported cases, however, is likely to be even higher. Glaucoma affects both men and women at a younger age. Acute glaucoma can strike at any age, but the risk rises significantly with age. Women are more vulnerable than men.
According to hospital quality reports, glaucoma treatment in Germany became more efficient from classical to modern treatment procedures after 2006, and it became a potential for stringent repayment guidelines.
The Indian Glaucoma treatment sector is expected to grow at a CAGR of 4.3% between 2023 and 2033.
Market expansion is fuelled by the rising elderly population as well as innovations in glaucoma and cataract surgery equipment technology. The development of micro-invasive glaucoma drainage implants, which are used to treat glaucoma and offer a safer and less intrusive means of reducing intraocular pressure (IOP) as compared to standard glaucoma surgery devices, is another area where manufacturers are placing more emphasis.
However, a shortage of qualified experts, a refusal to pay for the use of glaucoma and cataract surgical tools, and the exorbitant cost of cataract operation, particularly in emerging economies hinder market expansion. The government and other charitable groups' efforts to educate the public about the advantages of cataract surgery, eye problems, and the availability of cutting-edge technology have also opened up lucrative market potential in India.
Open angle Glaucoma disease type will contribute market share for about 81.35% in 2023 global market and it is expected to be stable through the forecast.
The most common type of glaucoma in the population is primary open angle glaucoma (POAG). According to a glaucoma genetics article published in the human molecular genetics journal, more than 57.5 million people worldwide were affected by POAG in 2020, with a global prevalence of 2.2%. As a result, rising glaucoma disease burden is expected to provide lucrative market growth opportunities.
The development of biologics is one of the main open angle glaucoma therapeutics industry trends driving market expansion. Several biologics are being developed for the treatment of open angle glaucoma. These drugs are expected to be more effective and safer than small molecules. As a result, it is expected that the development of such new biologics for the treatment of open angle glaucoma will meet the unmet need for an innovative and secure treatment of open-angle glaucoma, assisting the market to expand to a certain amount over the forecast period.
The prostaglandin analogue sector will hold a 33.36% market share in the global market for treating glaucoma in 2023 because ophthalmic drugs are becoming more widely accessible and available. Prostaglandin analogues are widely used to lower intraocular pressure due to their effectiveness, once-daily dose, lack of adverse effects, and improved recovery rates in the treatment of glaucoma, which will drive market demand. It is also projected that rising demand for prostaglandin medications in combination therapy would present the market with significant potential prospects. The overall market statistics will be further boosted by growing consumer awareness of early glaucoma therapy and an increase in the number of patients receiving early eye illness diagnosis.
Hospital pharmacies segment will hold the market share of 56.55% in 2023 globally. The demand for hospital pharmacies will be boosted by the increased availability of innovative medications.
In 2022, the hospital pharmacy segment was worth more than USD 3 billion. Throughout the analysis, the segment is expected to grow significantly. The significant growth is due to the widespread availability of products in various settings for various forms of glaucoma therapy.
Patient's preference for hospital pharmacies for prescribed medications also contributes to income growth. Reimbursement rules and insurance coverage for drug purchases made in hospital settings are also expected to improve market predictions.
The key companies in the glaucoma treatment are concentrating their efforts on partnerships and collaborations as the primary means of increasing their geographical presence. These will aid market participants in expanding both their new product launch and market penetration.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the glaucoma treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
| Key Market Segments Covered | Disease Type, Drug Class, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The global market of glaucoma treatment is worth US$ 5.7 Billion in 2022 and is set to expand 1.4X over the next ten years.
The global market in estimated to reach a valuation of US$ 5.8 Billion in 2023.
Between 2017 and 2022, the global market expanded at the rate of 3.0%.
The market of glaucoma treatment is expected to reach US$ 8.0 Billion by the end of 2033, with sales revenue expected to register 3.2% CAGR.
The global market is projected to expand at a CAGR of around 3.2% between 2023 and 2033.
The USA, China, Russia, Germany, and Canada are expected to drive demand for glaucoma treatment sector; and the market share of these top 5 countries will be 55.2% for the year 2022.
Europe is set to hold around 30.0% market share in the global market of glaucoma treatment in 2023.
AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd. are the key players of glaucoma treatment market.
Open angle Glaucoma disease type presents market share for about 81.35% in 2023 global market.
North America is one of the key markets for glaucoma treatment sector, with the USA to account for about 29.7% of the global glaucoma treatment sector in the year 2023.
The market is valued at US$ 5.8 billion in 2023.
A 3.2% CAGR is expected between 2023 and 2033 for the market.
In 2022, the top 5 countries held 55.2% of the market share.
The United States is estimated to generate a 29.8% share by 2033.
Open and glaucoma disease is to hold an 81.35% share in 2023.
1. Executive Summary | Glaucoma Treatment Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption/Usage Analysis 4.2. Key Promotional Strategies, by Manufacturers 4.3. Key Regulations 4.4. PESTEL Analysis 4.5. Porter’s Analysis 4.6. Disease Epidemiology 4.7. Pipeline Assessment 4.8. Reimbursement 4.9. Supply Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Eye Disorders & Diseases Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical & Current Growth 5.2.2. New Drug Launches and Approvals 5.2.3. Global Ophthalmic Epidemiology 5.2.4. R&D Expenditure by Key Players 5.2.5. Rising Consumer Awareness of the Eye Health 5.2.6. Rising Adoption of Glaucoma Treatment 5.2.7. Strategic Developments by Key Players 5.2.8. Increased Adoption of Therapies for Glaucoma 5.2.9. Strategic Collaborations among Players 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Disease Type 6.1.2. By Drug Class 6.1.3. By Distribution Channel 6.1.4. By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis by Disease Type, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Disease Type, 2023 to 2033 8.3.1. Open Angle Glaucoma 8.3.2. Angle Closure Glaucoma 8.3.3. Other 8.4. Market Attractiveness Analysis by Disease Type 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis by Drug Class, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Drug Class, 2023 to 2033 9.3.1. Prostaglandin Analog 9.3.2. Beta Blockers 9.3.3. Adrenergic Agonist 9.3.4. Carbonic Anhydrase Inhibitors 9.3.5. Others 9.4. Market Attractiveness Analysis by Drug Class 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis by Distribution Channel, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacy 10.3.2. Retail Pharmacy 10.3.3. Online Pharmacy 10.4. Market Attractiveness Analysis by Distribution Channel 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, by Region, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East & Africa 11.4. Market Attractiveness Analysis by Region 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. The USA 12.3.1.2. Canada 12.3.2. By Disease Type 12.3.3. BY Drug Class 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Disease Type 12.4.3. By Drug Class 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Disease Type 12.8.1.2.2. By Drug Class 12.8.1.2.3. By Distribution Channel 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Disease Type 12.8.2.2.2. By Drug Class 12.8.2.2.3. By Distribution Channel 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Disease Type 13.3.3. By Drug Class 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Disease Type 13.4.3. By Drug Class 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Disease Type 13.8.1.2.2. By Drug Class 13.8.1.2.3. By Distribution Channel 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Disease Type 13.8.2.2.2. By Drug Class 13.8.2.2.3. By Distribution Channel 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Disease Type 13.8.3.2.2. By Drug Class 13.8.3.2.3. By Distribution Channel 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. United Kingdom (UK) 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Disease Type 14.3.3. By Drug Class 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Disease Type 14.4.3. By Drug Class 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Disease Type 14.8.1.2.2. By Drug Class 14.8.1.2.3. By Distribution Channel 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Disease Type 14.8.2.2.2. By Drug Class 14.8.2.2.3. By Distribution Channel 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Disease Type 14.8.3.2.2. By Drug Class 14.8.3.2.3. By Distribution Channel 14.8.4. United Kingdom Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Disease Type 14.8.4.2.2. By Drug Class 14.8.4.2.3. By Distribution Channel 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Disease Type 14.8.5.2.2. By Drug Class 14.8.5.2.3. By Distribution Channel 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Disease Type 14.8.6.2.2. By Drug Class 14.8.6.2.3. By Distribution Channel 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Disease Type 14.8.7.2.2. By Drug Class 14.8.7.2.3. By Distribution Channel 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Disease Type 15.3.3. By Drug Class 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Disease Type 15.4.3. By Drug Class 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Disease Type 15.8.1.2.2. By Drug Class 15.8.1.2.3. By Distribution Channel 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Disease Type 15.8.2.2.2. By Drug Class 15.8.2.2.3. By Distribution Channel 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Disease Type 15.8.3.2.2. By Drug Class 15.8.3.2.3. By Distribution Channel 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Disease Type 16.3.3. By Drug Class 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Disease Type 16.4.3. By Drug Class 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Disease Type 16.8.1.2.2. By Drug Class 16.8.1.2.3. By Distribution Channel 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Disease Type 16.8.2.2.2. By Drug Class 16.8.2.2.3. By Distribution Channel 16.8.3. Malaysia Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Disease Type 16.8.3.2.2. By Drug Class 16.8.3.2.3. By Distribution Channel 16.8.4. Thailand Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Disease Type 16.8.4.2.2. By Drug Class 16.8.4.2.3. By Distribution Channel 17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Disease Type 17.3.3. By Drug Class 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Disease Type 17.4.2. By Drug Class 17.4.3. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Disease Type 17.8.1.2.2. By Drug Class 17.8.1.2.3. By Distribution Channel 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Disease Type 17.8.2.2.2. By Drug Class 17.8.2.2.3. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. North Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Disease Type 18.3.3. By Drug Class 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Disease Type 18.4.3. By Drug Class 18.4.4. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Disease Type 18.8.1.2.2. By Drug Class 18.8.1.2.3. By Distribution Channel 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Disease Type 18.8.2.2.2. By Drug Class 18.8.2.2.3. By Distribution Channel 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Disease Type 18.8.3.2.2. By Drug Class 18.8.3.2.3. By Distribution Channel 18.8.4. North Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Disease Type 18.8.4.2.2. By Drug Class 18.8.4.2.3. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. AERIE Pharmaceuticals, Inc. 20.3.1.1. Overview 20.3.1.2. Drug Type Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Key Financials 20.3.1.5. SWOT Analysis 20.3.1.6. Key Developments 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Type Strategy 20.3.1.7.3. Channel Strategy 20.3.2. Cipla Inc. 20.3.2.1. Overview 20.3.2.2. Drug Type Portfolio 20.3.2.3. Sales Footprint 20.3.2.4. Key Financials 20.3.2.5. SWOT Analysis 20.3.2.6. Key Developments 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Type Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Akorn Operating Company LLC 20.3.3.1. Overview 20.3.3.2. Drug Type Portfolio 20.3.3.3. Sales Footprint 20.3.3.4. Key Financials 20.3.3.5. SWOT Analysis 20.3.3.6. Key Developments 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Type Strategy 20.3.3.7.3. Channel Strategy 20.3.4. AbbVie 20.3.4.1. Overview 20.3.4.2. Drug Type Portfolio 20.3.4.3. Sales Footprint 20.3.4.4. Key Financials 20.3.4.5. SWOT Analysis 20.3.4.6. Key Developments 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Type Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Bausch & Lomb Incorporated 20.3.5.1. Overview 20.3.5.2. Drug Type Portfolio 20.3.5.3. Sales Footprint 20.3.5.4. Key Financials 20.3.5.5. SWOT Analysis 20.3.5.6. Key Developments 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Type Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Inoteck Pharmaceuticals 20.3.6.1. Overview 20.3.6.2. Drug Type Portfolio 20.3.6.3. Sales Footprint 20.3.6.4. Key Financials 20.3.6.5. SWOT Analysis 20.3.6.6. Key Developments 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Type Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Merck & Co. Inc. 20.3.7.1. Overview 20.3.7.2. Drug Type Portfolio 20.3.7.3. Sales Footprint 20.3.7.4. Key Financials 20.3.7.5. SWOT Analysis 20.3.7.6. Key Developments 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Type Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Novartis AG 20.3.8.1. Overview 20.3.8.2. Drug Type Portfolio 20.3.8.3. Sales Footprint 20.3.8.4. Key Financials 20.3.8.5. SWOT Analysis 20.3.8.6. Key Developments 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Type Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Pfizer Inc. 20.3.9.1. Overview 20.3.9.2. Drug Type Portfolio 20.3.9.3. Sales Footprint 20.3.9.4. Key Financials 20.3.9.5. SWOT Analysis 20.3.9.6. Key Developments 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Type Strategy 20.3.9.7.3. Channel Strategy 20.3.10. Santen Pharmaceutical Co. Ltd. 20.3.10.1. Overview 20.3.10.2. Drug Type Portfolio 20.3.10.3. Sales Footprint 20.3.10.4. Key Financials 20.3.10.5. SWOT Analysis 20.3.10.6. Key Developments 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Product Type Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Teva Pharmaceutical Industries Ltd. 20.3.11.1. Overview 20.3.11.2. Drug Type Portfolio 20.3.11.3. Sales Footprint 20.3.11.4. Key Financials 20.3.11.5. SWOT Analysis 20.3.11.6. Key Developments 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Product Type Strategy 20.3.11.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Glaucoma Treatment Market
